Skip to content

Effects of quetiapine and sertindole on subchronic ketamine-induced deficits in attentional set-shifting in rats.

Agnieszka Nikiforuk, Piotr Popik

Psychopharmacology September 15, 2011 DOI: 10.1007/s00213-011-2487-x (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Randomized controlled animal study Peer reviewed
Population Male Sprague-Dawley rats
Interventions Ketamine Quetiapine Sertindole
Dose Ketamine 30 mg/kg; quetiapine 0.63, 1.25, or 2.5 mg/kg; sertindole 2.5 mg/kg
Duration Ketamine once daily for 5 or 10 consecutive days; attentional set-shifting task performed 14 days after final ketamine dose; quetiapine or sertindole given 120 min before testing
Measures Attentional set-shifting task (ASST)
Topics Ketamine Esketamine
Keywords Animals Rats, sprague-dawley Disease models, animal Imidazoles Indoles Dibenzothiazepines Antipsychotic agents Attention Cognition disorders Schizophrenia Dose-response relationship, drug Male Quetiapine fumarate
Key points Ketamine given daily for 10 days, but not 5 days, produced a specific impairment in the extra-dimensional shift stage of an attentional set-shifting task 14 days after the last dose. Acute sertindole or quetiapine reversed this impairment, and quetiapine also improved set-shifting in cognitively unimpaired control rats. The authors argue this ketamine-induced deficit models clinically relevant cognitive dysfunction in schizophrenia.

Abstract

Rationale: Prefrontal cortical dysfunctions, including an impaired ability to shift perceptual attentional set, are core features of schizophrenia. Nevertheless, the effectiveness of second-generation antipsychotic drugs in treating specific prefrontal dysfunctions remains equivocal.

Objectives: To model schizophrenia-like cognitive inflexibility in rats, we evaluated the effects of repeated administration of ketamine, the noncompetitive antagonist of the N-methyl-D: -aspartate receptor, after a washout period of 14 days in the attentional set-shifting task (ASST). Next, we investigated whether the atypical antipsychotics quetiapine and sertindole would alleviate the ketamine-induced set-shifting impairment.

Methods: Ketamine (30 mg/kg) was administered intraperitoneally to rats once daily for 5 or 10 consecutive days to assess its efficacy in producing cognitive impairment. The ASST was performed 14 days following the final drug administration. Quetiapine (0.63, 1.25 or 2.5 mg/kg) or sertindole (2.5 mg/kg) was administered per os 120 min before testing.

Results: The results of the present study demonstrate that ketamine treatment for 10 but not 5 days significantly and specifically impaired rats' performance in the extra-dimensional shift (EDs) stage of the ASST. This cognitive inflexibility was reversed by acute administration of sertindole or quetiapine. Quetiapine also promoted set-shifting in cognitively unimpaired control animals.

Conclusion: The data presented here show that subchronic administration of ketamine induces cognitive inflexibility after a washout period. This cognitive deficit likely reflects clinically relevant aspects of cognitive dysfunction encountered in schizophrenic patients. The beneficial effects of quetiapine on set-shifting may have therapeutic implications for the treatment of schizophrenia and other disorders associated with frontal-dependent cognitive impairments.

Comparable studies

Other preclinical and animal studies on ketamine, most cited first.

Citations in the library

Explore topics